Novo Nordisk, Weight loss and diabetes drugs

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.